You have read all your free articles, to continue reading subscribe to read the rest of this content.
A1M Pharma’s manufacturing partner has completely manufactured the first large scale batch of the active substance in the candidate drug ROSGard and A1M Pharma has now decided to use this batch in the upcoming GLP toxicology studies. During 2016, A1M Pharma has performed an up-scaling of the maAlready a subscriber…
Vicore Pharma Holding has announced plans to initiate a clinical trial with C21 in Pulmonary arterial hypertension. Pulmonary arterial hypertension (PAH) is a rare lung disease with huge unmet medical need where existing medicines reduce the pressure by dilating the vessels without changing underAlready a subscriber Login You have read…
RhoVac's clinical phase IIb study of lead drug candidate RV001 in prostate cancer, BRaVac, is deemed fully recruited and no additional patients will be screened after this week. Top-line results of the study are estimated to be at hand in the first half of 2022, the company states. RhoVac starAlready…
The company has announced the dosing of the first patient in their first Phase 3 trial to evaluate dasiglucagon as a potential treatment option for children with CHI. “With the first child dosed, this Phase 3 trial takes an important step toward establishing dasiglucagon as a potential treatmenAlready a subscriber…
